

Published in final edited form as:

*Chem Biol Interact.* 2011 September 30; 193(3): 225–231. doi:10.1016/j.cbi.2011.07.001.

# MOLECULAR PATHOGENESIS OF HEPATIC FIBROSIS AND CURRENT THERAPEUTIC APPROACHES

**Elisabetta Mormone, Joseph George, and Natalia Nieto**

Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA

## Abstract

The pathogenesis of hepatic fibrosis involves significant deposition of fibrillar collagen and other extracellular matrix proteins. It is a rather dynamic process of wound healing in response to a variety of persistent liver injury caused by factors such as ethanol intake, viral infection, drugs, toxins, cholestasis and metabolic disorders. Liver fibrosis distorts the hepatic architecture, decreases the number of endothelial cell fenestrations and causes portal hypertension. Key events are the activation and transformation of quiescent hepatic stellate cells into myofibroblast-like cells with the subsequent up-regulation of proteins such as  $\alpha$ -smooth muscle actin, interstitial collagens, matrix metalloproteinases, tissue inhibitor of metalloproteinases and proteoglycans. Oxidative stress is a major contributing factor to the onset of liver fibrosis and it is typically associated with a decrease in the antioxidant defense. Currently, there is no effective therapy for advanced liver fibrosis. In its early stages, liver fibrosis is reversible upon cessation of the causative agent. In this review, we discuss some aspects on the etiology of liver fibrosis, the cells involved, the molecular pathogenesis and the current therapeutic approaches.

## Keywords

collagen; liver injury; stellate cells; extracellular matrix

## 1. Introduction

Fibrosis is the wound healing response to a variety of acute and/or chronic stimuli, including to name a few, ethanol, viral infection, drugs and toxins, cholestasis and metabolic disease [1–2]. Hepatic fibrosis develops due to an increase in fibrillar collagen synthesis and deposition along with insufficient remodeling [3–4]. Fibrosis is associated with a number of pathological and biochemical changes leading to structural and metabolic abnormalities, as well as with increased hepatic scarring [5–6]. The progression of liver fibrosis leads to cirrhosis, a condition characterized by distortion of the normal architecture, septae and nodule formation, altered blood flow, portal hypertension, hepatocellular carcinoma and ultimately liver failure [7].

© 2011 Elsevier Ireland Ltd. All rights reserved.

**Correspondence:** Natalia Nieto, Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA. Phone: +1-212-659-9217, Fax: +1-212-849-2574, natalia.nieto@mssm.edu.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Conflict of interest

The authors have no conflicts of interest to disclose

## 2. Etiology of hepatic fibrosis

Most chronic liver diseases are associated with fibrosis and are characterized by parenchymal damage and inflammation. Alcohol abuse, chronic viral hepatitis (HBV and HCV), obesity, autoimmune hepatitis, parasitic diseases (i.e. schistosomiasis), metabolic disorders (hemochromatosis and Wilson's disease), biliary disease, persistent exposure to toxins and chemicals and drug-induced chronic liver diseases are the most common causes of hepatic fibrosis.

### 2.1. Alcohol

Alcohol consumption is a predominant etiological factor in the pathogenesis of chronic liver diseases worldwide, resulting in fatty liver, alcoholic hepatitis, fibrosis/cirrhosis, and hepatocellular carcinoma [8]. Acetaldehyde, the product of alcohol metabolism via alcohol dehydrogenase, increases the secretion of transforming growth factor  $\beta$ 1 (TGF $\beta$ 1) and induces TGF $\beta$  type II receptor expression in hepatic stellate cells (HSC), the key collagen-producing cell within the liver [9]. Both, ethanol and acetaldehyde induce the *COL1A2* promoter and up-regulate collagen I protein expression [10]. In cultured human HSC, acetaldehyde up-regulates *COL1A1* mRNA expression via distinct mechanisms in the early and late responses [11]. Acetaldehyde-induced fibrogenesis involves a complex signaling pathway, which differs from that mediated by TGF $\beta$ 1 in the early time points to up-regulate *COL1A2* gene expression [11].

TGF $\beta$  1 is a critical factor in the progression of alcoholic liver disease (ALD) in patients with steatosis and steatohepatitis [12]. Acetaldehyde does not alter the Smad3 and Smad4 protein concentration; however, it selectively induces phosphorylation of Smad3 but not of Smad2 [13]. Weng *et al.* [12] identified a significant correlation of Smad2 phosphorylation with the fibrosis stage and the inflammation score. In addition, an association between serum pro-collagen III N-pro-peptide and TGF $\beta$  1 has been reported in patients with ALD [14]. These results demonstrate a significant role for TGF $\beta$  1 as mediator of alcohol-induced liver fibrosis.

Hepatic alcohol metabolism generates reactive oxygen species (ROS) causing significant cell death [15]. Indeed, oxidative stress, likely by increasing mitochondrial permeability transition, promotes hepatocyte necrosis and/or apoptosis. Generation of ROS within hepatocytes may be a consequence of an altered metabolic state, as it occurs in nonalcoholic fatty liver disease and non-alcoholic steatohepatitis. Alternatively, it could result from ethanol metabolism as in alcoholic steatohepatitis, with ROS being generated mainly by the mitochondrial electron transport chain, cytochrome P450 isoforms such as cytochrome P450 2E1 (CYP2E1), damaged mitochondria, xanthine oxidase, NADPH oxidase and generation of lipid peroxidation-end products [16]. In addition, it is known that chronic alcohol consumption lowers glutathione levels; thus, contributing to liver injury [17]. ROS-derived mediators released by damaged neighboring cells can directly affect the HSC behavior. ROS up-regulate the expression of critical genes related to fibrogenesis including pro-collagen type I, monocyte chemoattractant protein 1 (MCP-1) and tissue inhibitor of metalloproteinase-1 (TIMP1), possibly via activation of a number of critical signal transduction pathways and transcription factors, including c-*jun* N-terminal kinases (JNKs), activator protein 1 (AP-1) and nuclear factor kappa B (NF $\kappa$ B) [18].

### 2.2. Chronic viral hepatitis

Chronic hepatitis B and C virus are the most common causes of liver disease worldwide, with an estimated 350 and 170 million of individuals with chronic infection, respectively [19]. In addition, these infections are the primary cause of hepatocellular carcinoma (HCC).

In both cases, there is significant chronic liver injury with subsequent progression to advanced liver fibrosis and in many cases cirrhosis. While HBV can be integrated into the host genome leading to changes in genomic function or chromosomal instability, HCV cannot integrate into the host genome. Various HCV proteins, including the HCV core protein, the envelope and non-structural proteins present oncogenic properties. In HBV infection, antiviral therapy and vaccination decrease the risk of HCC. Current antiviral therapies for HCV such as ribavirin significantly reduce the risk of HCC.

### 2.3. Other causes of hepatic fibrosis

In addition to alcoholism and chronic viral hepatitis, other factors contributing to hepatic fibrosis are obesity and steatosis, which can lead to nonalcoholic fatty liver disease and to chronic steatohepatitis. Nonalcoholic fatty liver disease has also been reported in non-obese individuals in developing countries [20].

Autoimmune hepatitis, the anomalous presentation of human leukocyte antigen class II in hepatocytes, causes cell-mediated immune responses against the host liver, and may lead to liver fibrosis as well [21]. Parasitic infections like schistosomiasis, have been shown to trigger advanced liver fibrosis and portal hypertension [22].

Metabolic disorders such as hemochromatosis and Wilson's disease are typically accompanied by chronic hepatitis and fibrosis [23]. In hereditary hemochromatosis, the excessive absorption and accumulation of iron in tissues and organs including liver is related to mutations in the *HFE* (High-iron) gene [24]. Wilson's disease or hepatolenticular degeneration is a genetic disorder leading to copper accumulation in the liver and it is due to a mutation in the APTase (ATP7B) that transports copper [25].

Lastly, cholestasis due to bile duct obstruction, leads to chronic portal fibrosis and eventually cirrhosis. Moreover, chronic exposure to toxins or chemicals such as N-nitrosodimethylamine, carbon tetrachloride (CCl<sub>4</sub>) or thioacetamide leads to severe hepatic fibrosis in experimental animal models [26–28]. Exposure to these chemicals in humans is rare and generally occurs in the industry during manufacture and in places where these chemicals are routinely used.

## 3. Cell types involved in the pathogenesis of hepatic fibrosis

### 3.1. Hepatic stellate cells

Several cell types are involved in the pathogenesis of hepatic fibrosis. HSC reside in the *space of Disse* between hepatocytes and sinusoidal endothelial cells [29]. Quiescent HSC are characterized by significant expression of desmin and vitamin A storage. Following liver injury, HSC lose their vitamin A content, increase the expression of  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA), acquire a myofibroblast-like phenotype losing their typical star-shape, become proliferative, motile, pro-fibrogenic, contractile and show abundant rough endoplasmic reticulum [30].

Many factors have been identified to contribute to HSC activation. Damage to hepatocytes and Kupffer cell activation are still considered the primary effectors driving HSC activation [31–32]. Mediators released from damaged hepatocytes, such as lipid peroxidation products, intermediate metabolites of drugs or hepatotoxins, acetaldehyde and 1-hydroxyethyl radical from alcohol metabolism as well as ROS (hydrogen peroxide, superoxide radical and others) are strong inducers of HSC activation.

Activated Kupffer cells release ROS and cytokines that are crucial for HSC activation as well [32]. They are a major source of TGF $\beta$  and platelet-derived growth factor (PDGF), two

potent profibrogenic cytokines that traditionally have been considered key fibrogenic and proliferative stimuli to HSC, respectively [33]. In addition, the Kupffer cell phagocytic activity generates large amounts of ROS that could further activate HSC and induce their fibrogenic potential.

We have previously demonstrated that cytochrome P450 2E1-dependent generation of ROS is critical for increased collagen I protein synthesis in co-cultures of hepatocytes and HSC [31]. Furthermore, addition of ethanol and arachidonic acid synergized to activate Kupffer cells and modulated the fibrogenic response by a mechanism involving TNF $\alpha$ , reduced glutathione and TGF $\beta$  [34].

It has been also demonstrated that *in vivo* ablation of TNF $\alpha$ , TLR4, CD14 and lipopolysaccharide-binding protein protects from the fibrogenic response [35]. Despite the close association of inflammation and fibrosis, little is known on the crosstalk between these two key events and the intracellular signal transduction pathways activated. For example, TLR4 is activated by lipopolysaccharide in Kupffer cells leading to NF $\kappa$ B and IRF3 activation, and the subsequent transcriptional activation of pro-inflammatory mediators such as TNF $\alpha$  and IFN $\gamma$ . Moreover, TNF $\alpha$  activates the NF $\kappa$ B signaling pathway in hepatocytes, which is key for their survival [8, 36]. However, there is no crosstalk with the TGF $\beta$  pathway that results in the activation of Smad3 and Smad4 and the associated induction of TGF $\beta$ -responsive genes.

### 3.2. Portal fibroblasts

The portal connective tissue in healthy liver is surrounded by quiescent portal fibroblasts, which constitute a second population of liver cells implicated in portal fibrosis [37]. Derived from small portal vessels, they express markers distinct from HSC (e.g. elastin) [38]. Proliferation of biliary cells is often accompanied by proliferation of portal fibroblasts, which form onion-like configurations around biliary structures and acquire a myofibroblast phenotype, and are thus implied in the early deposition of extracellular matrix (ECM) in portal zones [39]. It is generally believed that substantial signaling from biliary epithelial cells leads to portal fibroblast activation, although the key factors remain to be identified.

### 3.3. Bone marrow-derived mesenchymal stem cells

Several studies have indicated that bone marrow derived mesenchymal stem cells could be a source of multi-lineage cells for various organs. They have the capacity to differentiate into hepatocytes, biliary epithelial cells, sinusoidal endothelial cells and even Kupffer cells in the presence of a suitable hepatic microenvironment [40–41]. There is growing evidence to suggest that bone marrow-derived stem cells are recruited during both progression and regression of liver fibrosis. During regression from CCl<sub>4</sub> induced hepatic fibrosis, bone marrow-derived mesenchymal stem cells migrate into the fibrotic liver, where they can express matrix metalloprotease-13 (MMP13) and MMP9 [42]. In addition, granulocyte colony-stimulating factor and hepatocyte growth factor treatment significantly enhance migration of bone marrow-derived cells into the fibrotic liver and accelerate the regression of liver fibrosis [43]. Over-expression of hepatocyte growth factor together with granulocyte colony-stimulating factor, synergistically stimulate MMP9 expression, which is followed by accelerated resolution of fibrotic scars [44]. A significant contribution of bone marrow-derived cells has been shown in human liver fibrosis, but it is unclear the specific type of mesenchymal stem cells [45].

### 3.4. Hepatocytes and biliary epithelial cells

Epithelial-to-mesenchymal transition (EMT) is now emerging as a possible source of injury-associated mesenchymal cells, derived either from resident hepatocytes or from biliary

epithelial cells [46–47], although its role in liver fibrosis is still controversial [48–49]. The main molecules inducing EMT are TGF $\beta$ , epidermal growth factor, insulin-like growth factor-II and fibroblast growth factor-2 [50]. Hepatocytes that express albumin also express fibroblast-specific protein-1 in response to CCl<sub>4</sub> *in vivo* or to TGF $\beta$ 1 *in vitro* [50]. Kaimori *et al.* [51] reported that hepatocytes express *COL1A1* in response to TGF $\beta$ 1 *in vitro*, and that Smad signaling mediates EMT.

On the contrary, a recent study shows that hepatocytes isolated from mice chronically treated with CCl<sub>4</sub>, neither express mesenchymal markers nor exhibit a phenotype clearly distinguishable from control hepatocytes [52]. In order to confirm this, Scholten *et al.* [53] studied EMT using the Cre-LoxP system to map the cell fate of CK19<sup>+</sup> cholangiocytes in CK19 (YFP) or fibroblast-specific protein-1 (FSP-1) (YFP) mice. Mice were bile duct ligated or subjected to CCl<sub>4</sub>-induced liver injury and the livers were analyzed for expression of mesoderm and epithelium markers. The results demonstrated that EMT of cholangiocytes does not contribute to hepatic fibrosis in mice. Likewise, GFAP (Cre)-labeled HSC showed no co-expression of epithelial markers, providing no evidence for EMT in HSC in response to fibrogenic liver injury [53].

Biliary epithelial cells have been described to be involved in EMT in liver fibrogenesis. In primary biliary cirrhosis, it has been shown that cells of the bile duct express fibroblast-specific protein-1 and vimentin, early markers of fibroblasts [54]. A consequence of EMT in biliary epithelial cells is the amplification of the pool of portal fibroblasts, contributing significantly to portal fibrosis. *In vitro* studies with human biliary epithelial cells have confirmed these clinical observations [55]. Thus, EMT could be considered a mechanism participating in the pathogenesis of chronic cholestatic liver disease. However, additional research is necessary to validate this possibility.

### 3.5. Fibrocytes

Fibrocytes constitute a circulating bone marrow-derived CD34<sup>+</sup> cell subpopulation with fibroblast-like properties initially associated with tissue repair in subcutaneous wounds [56]. They comprise a fraction of about 1% of the circulating pool of leukocytes expressing markers of mesenchymal cells [57]. Subsequently, two studies have demonstrated the bone marrow origin of fibrogenic cell populations in the CCl<sub>4</sub> mouse model of fibrosis and in the bile duct ligation model of biliary hyperplasia [58–59]. Roderfeld *et al.* [60] hypothesized that bone marrow-derived circulating CD34<sup>+</sup> fibrocytes represent key mediators of liver fibrogenesis in the *Abcb4*<sup>-/-</sup> mice, which represent a highly reproducible, well-characterized non-surgical mouse model for cholangiopathy in humans.

## 4. Molecular pathogenesis of hepatic fibrosis

Figure 1 summarizes key concepts involved in the molecular pathogenesis of liver fibrosis. A recent review by Hernandez-Gea *et al* [61] provides more insight into the pathogenesis of hepatic fibrosis.

### 4.1. Cell-cell and cell-matrix interactions

Alterations in normal cell-cell and cell-matrix interactions play a significant role in pathogenesis of hepatic fibrosis. When normal cell-cell and cell-matrix interactions are altered due to hepatocyte necrosis or invasion of inflammatory cells, new interactions are established that trigger a fibrogenic response. In the fibrotic liver, significant quantitative and qualitative changes occur in the composition of ECM in the periportal and perisinusoidal areas. During cirrhosis, the amount of fibrillar collagens and proteoglycans can be up to six times higher than in healthy livers [62–63]. The scar is typically composed of fibrillar collagen type I and III, proteoglycans, fibronectin and hyaluronic acid [64]. As a



result, alteration in the physiological architecture of the liver occurs, particularly in the *space of Disse*, where the low electron-dense ECM is replaced by one rich in fibrillar collagens and fibronectin [61]. This leads to loss of endothelial cell fenestrations, impaired exchange of solutes among neighboring cells, altered hepatocyte function and subsequent non-parenchymal cell damage [61]. Previous work from our group has shown that co-culture of Kupffer cells or hepatocytes with HSC induces a more activated phenotype, greater proliferation rates and increased collagen synthesis in HSC compared to HSC cultured alone [31, 32, 65].

#### 4.2. Oxidative stress

Chronic HBV infection and long-term consumption of alcohol induce cell damage through increased generation of ROS [66]. Indeed, oxidative stress, which favors mitochondrial permeability transition, is able to promote hepatocyte necrosis and/or apoptosis. In some clinically relevant conditions, generation of ROS within hepatocytes may represent an altered metabolic state as in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, or significant ethanol metabolism as it occurs in alcoholic steatohepatitis. ROS are generated mainly via the mitochondrial electron transport chain or via activation of cytochrome P450 -mostly cytochrome P450 2E1-, NADPH oxidase, xanthine oxidase or via mitochondrial damage. The ROS generated can directly affect the HSC and myofibroblasts behavior [32, 67]. ROS up-regulate the expression of critical fibrosis-associated genes such as *COL1A1*, *COL1A2*, *MCPI* and *TIMP1* via activation of signal transduction pathways and transcription factors, including JNK, activator protein-1 and NF $\kappa$ B [18]. ROS generation in HSC and myofibroblasts occurs in response to several known pro-fibrogenic mediators, including angiotensin II, PDGF, TGF $\beta$  and leptin [68]. Overall, a decrease in the antioxidant defense such as GSH, catalase or SOD, in conjunction with enhanced lipid peroxidation leads to a pro-fibrogenic response by enhancing collagen I protein expression [69].

#### 4.3. Role of MMPs and TIMPs

The ECM is a highly dynamic *milieu* subject to constant remodeling whereby synthesis of new components occurs with simultaneous degradation. Life-threatening pathological conditions arise when ECM remodeling becomes excessive or uncontrolled. Among the cells involved in hepatic ECM degradation are HSC, neutrophils and macrophages. MMPs are the main enzymes responsible for ECM degradation and TIMPs have the ability to inhibit MMPs [70]. Therefore, regulation of the MMP-TIMP balance is crucial for efficient ECM remodeling. The MMP-TIMP ratio is tipped because of multiple pro-fibrogenic insults. Activated HSC not only synthesize and secrete ECM proteins such as collagens type I and type III, but also produce MMP1 [71] and MMP13 [72]. However, MMP1 and MMP13 expression decreases as HSC activation progresses, while the activity of other MMPs remains relatively constant, except for MMP2 and MMP9 [73]. The increase in MMP2 activity is associated with distortion of the normal lobular architecture, which further activates HSC [73]. Moreover, activated HSC up-regulate the expression and synthesis of TIMP1 and TIMP2 [74]. TIMP1 not only prevents the degradation of the rapidly increasing ECM by blocking MMPs, but also inhibits the apoptosis of activated HSC [75]. The net result is the deposition of mature collagen fibers within the *space of Disse* and thus scarring.

As indicated above, scar formation is regulated by the balance between MMPs and TIMPs, which are induced by ROS and RNS in the CCl<sub>4</sub> model of liver fibrosis [76]. This was elucidated in a study using a mutant form of MMP9 that scavenged TIMP1 and inhibited CCl<sub>4</sub>-induced fibrosis [77]. Thus, TIMP1 activity may be a crucial factor in the regression of fibrosis. Several factors can activate TIMP1, including leptin [78], angiotensin II [79], and sphingosine 1 phosphate [80]. The delineation of the signaling pathways elicited by these factors is important for successful inhibition of TIMP1 activity. Increased liver MMP

activity either by recruitment of bone marrow-derived cells or by decreasing TIMP1 level may lead to regression of fibrosis [81].

## 5. Current therapies for hepatic fibrosis

Despite significant advances in understanding hepatic fibrosis and defining targets for therapy, there are limited anti-fibrotic drugs approved for clinical use in patients with advanced liver disease. Regression of established fibrosis can be accomplished in selected individuals with chronic liver diseases that have effective interferon therapies [82]. However, a large cohort of patients does not respond to conventional treatment and thus remain at risk for progression of fibrosis to cirrhosis.

Ideally, the anti-fibrotic therapy should be liver-specific, selective for targeting of the fibrogenic cascade, including inhibition of matrix deposition, collagen synthesis, modulation of HSC activation, enhancing matrix degradation, stimulating HSC death or apoptosis, and it should be well tolerated if administered for a prolonged period. Several compounds including colchicine and malotilate, with potential antifibrotic activity, have been studied in human trials but found to be not very effective [83–84]. The ideal anti-fibrotic agent, which should be safe when used over a long period, liver-specific, non-hepatotoxic, for oral administration and inexpensive is not yet available.

Many agents such as malotilate, genistein, curcumin and silymarin have been shown to be effective *in vitro* and in experimental animal models [84–86]. Although there are no perfect and effective anti-fibrogenic agents, the potential candidates include agents that can reduce inflammation and the immune response such as corticosteroids, colchicines and IL-10; agents that reduce the activation of ECM-producing cells as well as their pro-fibrogenic potential such as inhibitors of TGF $\beta$ 1, INF $\alpha$  and peroxisome proliferator activated receptor- $\gamma$  agonists [87]; antioxidants such as vitamin E [88], phosphatidylcholine [89] and S-adenosyl-L-methionine [90]; N-acetylcysteine and 5-nitroso-N-acetylcysteine [91], which appears to be more efficient, agents capable of increase the degradation of ECM fibrillar such as MMPs and uroplasminogen activator [92] and interferons [93]. Combination therapy that works at different mechanistic levels would be more appropriate to block HSC activation and the pathogenesis of liver fibrosis.

## 6. Molecular therapy for hepatic fibrosis

Compared with other antisense strategies such as antisense oligonucleotides, ribozymes or DNazymes, siRNA has been proved to be a potent knockdown of any given target gene with high sequence specificity [94]. Hence, siRNA would be a powerful strategy to treat liver fibrosis in the future. There are three ways to deliver siRNA: synthetic duplex, plasmid and viral vectors. While viral vectors give high transduction efficiency, their immune reactions limit their application in therapeutics. On the other hand, plasmid DNA complexes with cationic liposomes may not pass through sinusoidal gaps, because endothelial cells fenestrations are closed during liver fibrosis. In contrast, low molecular weight synthetic duplex siRNA is likely to pass through sinusoidal gaps in fibrotic livers, and thus they may be ideal candidates for treating liver fibrosis [95].

Most of the targeted genes are those critical for HSC activation, proliferation, and/or collagen synthesis and deposition, which are usually markedly up-regulated during hepatic fibrogenesis, including CTGF, TGF $\beta$ 1, PDGF, TIMPs and plasminogen activator inhibitor-1 [96]. However, these molecules may also play a role in many physiological processes and their inhibition may lead to adverse side effects. Cheng *et al.* [95] have successfully designed and validated TGF $\beta$ 1-specific siRNAs and then converted two potent siRNA sequences into shRNAs, which effectively silenced TGF $\beta$ 1 gene expression in HSC cells.

TGF $\beta$ 1 gene silencing significantly reduced the production of collagen I, TIMP1 and inflammatory cytokines [95]. Their results suggested that silencing TGF $\beta$ 1 by siRNA and shRNA may be an efficient and more specific approach for treating liver fibrosis [95]. Another study [97] showed that inhibiting the receptor for advanced glycation end products (RAGE) gene, which is involved in migration of activated HSC and myofibroblasts [98], by a specific RAGE siRNA expression vector, inhibited the expression of collagen I in CCl<sub>4</sub>-induced rat liver fibrosis and dramatically reduced the levels of serum pro-collagen type III, hyaluronic acid and laminin. These results indicated that inhibition of RAGE had important antifibrogenic effects [98]. However, the mechanisms of the effects of RAGE on the accumulation of ECM in hepatic fibrosis need further investigation.

Using the RAGE specific siRNA strategy, they effectively inhibited RAGE gene expression in rat liver fibrosis and successfully prevented experimental liver fibrosis in rats [98]. The suppression of the up-regulated expression and activity of NF $\kappa$ B and HSC activation via inhibition of I $\kappa$ B $\alpha$  degradation, inhibition of ECM production and attenuation of liver injury may be possible strategies to prevent liver fibrosis by inhibiting RAGE. These findings strongly suggests that RAGE may be a new target for combating liver fibrosis and RAGE specific siRNA might be an effective candidate to prevent liver fibrosis.

Based on recent studies, micro RNAs (miRNAs) have gained significant interest as diagnostic biomarkers and as therapeutic targets. miRNAs belong to a class of small, non-coding RNA molecules that control protein expression at the post-transcriptional level [99]. Their mechanism of action involves imperfect binding to complementary sequences in the 3'-untranslated region of target mRNAs, leading to either cleavage of the mRNA [100] or suppression of protein translation [101]. In liver fibrosis, activation of HSC, which is regulated by multiple signal transduction pathways, is considered a key event; thus, proteins from the pathways involved could be important targets for miRNAs.

In order to understand the critical pathways of HSC activation, Guo *et al.* [102] performed comprehensive comparative bioinformatics analysis of microarrays of quiescent and activated HSC. Changes in miRNAs associated with HSC activation status revealed that 13 pathways were up-regulated and 22 pathways were down-regulated by miRNA. Lee and colleagues dissected a novel mechanism for cystogenesis involving miRNA [103]. They demonstrated that levels of the miRNA, miR15a are decreased in livers of patients with autosomal recessive and autosomal dominant polycystic kidney disease and congenital hepatic fibrosis as well as in the *PKC* rat model of autosomal recessive polycystic kidney disease. This results in increased expression of the cell-cycle regulator Cdc25A, which is a direct target of miR15a, and increased cellular proliferation and cystogenesis *in vitro*.

Roderburg *et al.* [104] studied the regulation of miRNAs in experimentally induced hepatic fibrosis by microarray. They found that three members of the miR-29-family are significantly down-regulated in livers of CCl<sub>4</sub>-treated mice as well as in mice that underwent bile duct ligation [104]. Specifically, their data indicate that miR-29 mediates the regulation of liver fibrosis and it is part of a signaling nexus involving TGF $\beta$ - and NF $\kappa$ B-dependent down-regulation of miR-29 family members in HSC with the subsequent up-regulation of ECM genes [104]. Therefore, identifying potential miRNAs for the arrest of HSC activation and proliferation could lead to therapeutic intervention of hepatic fibrosis.

## 7. Conclusion

Understanding the mechanisms and the pathways involved in the pathogenesis of the fibrogenic response could provide novel therapeutic approaches for liver diseases in which fibrosis is a detrimental component. Identifying potential new therapeutic agents that target



specific pathways involved in fibrosis is critical to overcome the barriers to progress in the field of liver fibrosis. Thus, prevention of hepatic fibrosis could help ameliorate the complications of cirrhosis, and improve the quality of life of many patients worldwide.

#### Research Highlights for

#### **MOLECULAR PATHOGENESIS OF HEPATIC FIBROSIS AND CURRENT THERAPEUTIC APPROACHES**

- We evaluated different aspects of the etiology of liver fibrosis
- Delineated the molecular mechanism of the pathogenesis of hepatic fibrosis
- Discussed all current therapeutic approaches including molecular gene therapy

## Acknowledgments

**Grant Support:** US Public Health Service Grants 5R01 DK069286 and 2R56 DK069286 from the National Institute of Diabetes and Digestive and Kidney Diseases and 5P20 AA017067 from the National Institute on Alcohol Abuse and Alcoholism (N. N.).

## Abbreviations

<b>ALD</b>	alcoholic liver disease
<b>AP1</b>	activator protein 1
<b><math>\alpha</math>-SMA</b>	$\alpha$ -smooth muscle actin
<b>CCl<sub>4</sub></b>	carbon tetrachloride
<b>CYP2E1</b>	cytochrome P450 2E1
<b>ECM</b>	extracellular matrix
<b>EMT</b>	epithelial-to-mesenchymal transition
<b>HBV</b>	hepatitis B virus
<b>HCC</b>	hepatocellular carcinoma
<b>HCV</b>	hepatitis C virus
<b>HSC</b>	hepatic stellate cells
<b>JNK</b>	c- <i>jun</i> N-terminal kinase
<b>MCP1</b>	monocyte chemoattractant protein 1
<b>miRNA</b>	micro RNA
<b>MMP</b>	matrix metalloproteinase
<b>NF<math>\kappa</math>B</b>	nuclear factor kappa B
<b>PDGF</b>	platelet-derived growth factor
<b>RAGE</b>	advanced glycation-end products
<b>ROS</b>	reactive oxygen species
<b>TGF<math>\beta</math>1</b>	transforming growth factor $\beta$ 1
<b>TIMP1</b>	tissue inhibitor of metalloproteinase 1

## References

- Schuppan D. Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. *Semin Liver Dis.* 1990; 10(1):1–10. [PubMed: 2186485]
- Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. *J Clin Pathol.* 1978; 31(5):395–414. [PubMed: 649765]
- Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. *J Biol Chem.* 2000; 275(4):2247–2250. [PubMed: 10644669]
- George J, Rao KR, Stern R, Chandrakasan G. Dimethylnitrosamine-induced liver injury in rats: the early deposition of collagen. *Toxicology.* 2001; 156(2–3):129–138. [PubMed: 11164615]
- Bissell DM. Cell-matrix interaction and hepatic fibrosis. *Prog Liver Dis.* 1990; 9:143–155. [PubMed: 2156289]
- George J, Chandrakasan G. Biochemical abnormalities during the progression of hepatic fibrosis induced by dimethylnitrosamine. *Clin Biochem.* 2000; 33(7):563–570. [PubMed: 11124342]
- Han YP, Zhou L, Wang J, Xiong S, Garner WL, French SW, Tsukamoto H. Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. *J Biol Chem.* 2004; 279(6):4820–4828. [PubMed: 14617627]
- Miller AM, Horiguchi N, Jeong WI, Radaeva S, Gao B. Molecular Mechanisms of Alcoholic Liver Disease: Innate Immunity and Cytokines. *Alcoholism-Clinical and Experimental Research.* 2011; 35(5):787–793.
- Anania FA, Potter JJ, Rennie-Tankersley L, Mezey E. Activation by acetaldehyde of the promoter of the mouse alpha2(I) collagen gene when transfected into rat activated stellate cells. *Arch Biochem Biophys.* 1996; 331(2):187–193. [PubMed: 8660697]
- Chen A. Acetaldehyde stimulates the activation of latent transforming growth factorbeta1 and induces expression of the type II receptor of the cytokine in rat cultured hepatic stellate cells. *Biochem J.* 2002; 368(Pt 3):683–693. [PubMed: 12223100]
- Svegliati-Baroni G, Inagaki Y, Rincon-Sanchez AR, Else C, Saccomanno S, Benedetti A, Ramirez F, Rojkind M. Early response of alpha2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-beta independent. *Hepatology.* 2005; 42(2):343–352. [PubMed: 16025520]
- Weng HL, Liu Y, Chen JL, Huang T, Xu LJ, Godoy P, Hu JH, Zhou C, Stickel F, Marx A, Bohle RM, Zimmer V, Lammert F, Mueller S, Gigou M, Samuel D, Mertens PR, Singer MV, Seitz HK, Dooley S. The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. *Hepatology.* 2009; 50(1):230–243. [PubMed: 19441105]
- Greenwel P, Dominguez-Rosales JA, Mavi G, Rivas-Estilla AM, Rojkind M. Hydrogen peroxide: a link between acetaldehyde-elicited alpha1(I) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells. *Hepatology.* 2000; 31(1):109–116. [PubMed: 10613735]
- Stickel F, Urbaschek R, Schuppan D, Poeschl G, Oesterling C, Conradt C, McCuskey RS, Simanowski UA, Seitz HK. Serum collagen type VI and XIV and hyaluronic acid as early indicators for altered connective tissue turnover in alcoholic liver disease. *Digest Dis Sci.* 2001; 46(9):2025–2032. [PubMed: 11575459]
- Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. *J Hepatol.* 2001; 35(2):297–306. [PubMed: 11580156]
- Haorah J, Ramirez SH, Floreani N, Gorantla S, Morsey B, Persidsky Y. Mechanism of alcohol-induced oxidative stress and neuronal injury. *Free Radic Biol Med.* 2008; 45(11):1542–1550. [PubMed: 18845238]
- Cederbaum AI. Hepatoprotective effects of S-adenosyl-L-methionine against alcohol- and cytochrome P450 2E1-induced liver injury. *World J Gastroenterol.* 2010; 16(11):1366–1376. [PubMed: 20238404]
- Bataller R, Brenner DA. Liver fibrosis. *Journal of Clinical Investigation.* 2005; 115(2):209–218. [PubMed: 15690074]

19. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. *J Clin Gastroenterol*. 2004; 38(10):S158–S168. [PubMed: 15602165]
20. Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, Dhibar T, Bhattacharya B, Bhattacharya D, Manna B, Dhali GK, Santra A, Chowdhury A. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. *Hepatology*. 2010; 51(5): 1593–1602. [PubMed: 20222092]
21. Lim YS, Oh HB, Choi SE, Kwon OJ, Heo YS, Lee HC, Suh DJ. Susceptibility to type 1 autoimmune hepatitis is associated with shared amino acid sequences at positions 70–74 of the HLA-DRB1 molecule. *Journal of Hepatology*. 2008; 48(1):133–139. [PubMed: 18022727]
22. Andersson KL, Chung RT. Hepatic schistosomiasis. *Curr Treat Options Gastroenterol*. 2007; 10(6):504–512. [PubMed: 18221611]
23. Lefkowitz JH. Hepatobiliary pathology. *Curr Opin Gastroenterol*. 2006; 22(3):198–208. [PubMed: 16550033]
24. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A. The discovery of the new haemochromatosis gene. 1996. *J Hepatol*. 2003; 38(6):704–709. [PubMed: 12763361]
25. Zhang S, Chen S, Li W, Guo X, Zhao P, Xu J, Chen Y, Pan Q, Liu X, Zychlinski D, Lu H, Tortorella MD, Schambach A, Wang Y, Pei D, Esteban MA. Rescue of ATP7B function in hepatocyte-like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin. *Hum Mol Genet*. 2011
26. George J, Tsutsumi M. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats. *Gene Therapy*. 2007; 14(10):790–803. [PubMed: 17344905]
27. Domenicali M, Caraceni P, Giannone F, Baldassarre M, Lucchetti G, Quarta C, Patti C, Catani L, Nanni C, Lemoli RM, Bernardi M. A novel model of CCl4-induced cirrhosis with ascites in the mouse. *Journal of Hepatology*. 2009; 51(6):991–999. [PubMed: 19853952]
28. Salguero Palacios R, Roderfeld M, Hemmann S, Rath T, Atanasova S, Tschuschner A, Gressner OA, Weiskirchen R, Graf J, Roeb E. Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice. *Lab Invest*. 2008; 88(11):1192–1203. [PubMed: 18794850]
29. Friedman SL. Mechanisms of hepatic fibrogenesis. *Gastroenterology*. 2008; 134(6):1655–1669. [PubMed: 18471545]
30. Gressner AM. Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: A key event in hepatic fibrogenesis. *Kidney International*. 1996; 49:S39–S45. [PubMed: 8731193]
31. Nieto N, Friedman SL, Cederbaum AI. Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. *J Biol Chem*. 2002; 277(12):9853–9864. [PubMed: 11782477]
32. Nieto N. Oxidative-stress and IL-6 mediate the fibrogenic effects of rodent Kupffer cells on stellate cells. *Hepatology*. 2006; 44(6):1487–1501. [PubMed: 17133487]
33. Tsukamoto H. Cytokine regulation of hepatic stellate cells in liver fibrosis. *Alcoholism-Clinical and Experimental Research*. 1999; 23(5):911–916.
34. Cubero FJ, Nieto N. Ethanol and Arachidonic Acid Synergize to Activate Kupffer Cells and Modulate the Fibrogenic Response via Tumor Necrosis Factor alpha, Reduced Glutathione, and Transforming Growth Factor beta-Dependent Mechanisms. *Hepatology*. 2008; 48(6):2027–2039. [PubMed: 19003881]
35. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: Update. *Hepatology*. 2008; 48(1):322–335. [PubMed: 18506843]
36. Gao B, Seki E, Brenner DA, Friedman S, Cohen JI, Nagy L, Szabo G, Zakhari S. Innate immunity in alcoholic liver disease. *Am J Physiol Gastrointest Liver Physiol*. 2011; 300(4):G516–G525. [PubMed: 21252049]
37. Tuchweber B, Desmouliere A, BochatonPiallat ML, RubbiaBrandt L, Gabbiani G. Proliferation and phenotypic modulation of portal fibroblasts in the early stages of cholestatic fibrosis in the rat. *Laboratory Investigation*. 1996; 74(1):265–278. [PubMed: 8569191]


38. Li Z, Dranoff JA, Chan EP, Uemura M, Seigny J, Wells RG. Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. *Hepatology*. 2007; 46(4): 1246–1256. [PubMed: 17625791]
39. Desmouliere A, Darby I, Costa AM, Raccurt M, Tuchweber B, Sommer P, Gabbiani G. Extracellular matrix deposition, lysyl oxidase expression, and myofibroblastic differentiation during the initial stages of cholestatic fibrosis in the rat. *Lab Invest*. 1997; 76(6):765–778. [PubMed: 9194853]
40. Gao Z, McAlister VC, Williams GM. Repopulation of liver endothelium by bone-marrow-derived cells. *Lancet*. 2001; 357(9260):932–933. [PubMed: 11289353]
41. Fujii H, Hirose T, Oe S, Yasuchika K, Azuma H, Fujikawa T, Nagao M, Yamaoka Y. Contribution of bone marrow cells to liver regeneration after partial hepatectomy in mice. *J Hepatol*. 2002; 36(5):653–659. [PubMed: 11983449]
42. Chang YJ, Liu JW, Lin PC, Sun LY, Peng CW, Luo GH, Chen TM, Lee RP, Lin SZ, Harn HJ, Chiou TW. Mesenchymal stem cells facilitate recovery from chemically induced liver damage and decrease liver fibrosis. *Life Sci*. 2009; 85(13–14):517–525. [PubMed: 19686763]
43. Higashiyama R, Inagaki Y, Hong YY, Kushida M, Nakao S, Niioka M, Watanabe T, Okano H, Matsuzaki Y, Shiota G, Okazaki I. Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice. *Hepatology*. 2007; 45(1):213–222. [PubMed: 17187438]
44. Bird TG, Lorenzini S, Forbes SJ. Activation of stem cells in hepatic diseases. *Cell Tissue Res*. 2008; 331(1):283–300. [PubMed: 18046579]
45. Forbes SJ, Russo FP, Rey V, Burra P, Rugge M, Wright NA, Alison MR. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. *Gastroenterology*. 2004; 126(4):955–963. [PubMed: 15057733]
46. Dooley S, Hamzavi J, Ciucan L, Godoy P, Ilkavets I, Ehnert S, Ueberham E, Gebhardt R, Kanzler S, Geier A, Breitkopf K, Weng H, Mertens PR. Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. *Gastroenterology*. 2008; 135(2):642–659. [PubMed: 18602923]
47. Nitta T, Kim JS, Mohuczy D, Behrns KE. Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. *Hepatology*. 2008; 48(3): 909–919. [PubMed: 18712785]
48. Wells RG. The epithelial-to-mesenchymal transition in liver fibrosis: here today, gone tomorrow? *Hepatology*. 2010; 51(3):737–740. [PubMed: 20198628]
49. Kisseleva T, Brenner DA. Is it the end of the line for the EMT? *Hepatology*. 2011; 53(5):1433–1435. [PubMed: 21433040]
50. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, Kalluri R. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. *J Biol Chem*. 2007; 282(32):23337–23347. [PubMed: 17562716]
51. Kaimori A, Potter J, Kaimori JY, Wang C, Mezey E, Koteish A. Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. *J Biol Chem*. 2007; 282(30):22089–22101. [PubMed: 17513865]
52. Taura K, Miura K, Iwaisako K, Osterreicher CH, Kodama Y, Penz-Osterreicher M, Brenner DA. Hepatocytes Do Not Undergo Epithelial-Mesenchymal Transition in Liver Fibrosis in Mice. *Hepatology*. 2010; 51(3):1027–1036. [PubMed: 20052656]
53. Scholten D, Osterreicher CH, Scholten A, Iwaisako K, Gu G, Brenner DA, Kisseleva T. Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice. *Gastroenterology*. 2010; 139(3):987–998. [PubMed: 20546735]
54. Robertson H, Kirby JA, Yip WW, Jones DEJ, Burt AD. Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis. *Hepatology*. 2007; 45(4):977–981. [PubMed: 17393507]
55. Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, Jones DE, Burt AD, Kirby JA. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. *Lab Invest*. 2008; 88(2):112–123. [PubMed: 18059363]

56. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. *Mol Med.* 1994; 1(1):71–81. [PubMed: 8790603]
57. Moore BB, Kolodnick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, Toews GB. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. *Am J Pathol.* 2005; 166(3):675–684. [PubMed: 15743780]
58. Kisseleva T, Uchinami H, Feirt N, Quintana-Bustamante O, Segovia JC, Schwabe RF, Brenner DA. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. *J Hepatol.* 2006; 45(3):429–438. [PubMed: 16846660]
59. Russo FP, Alison MR, Bigger BW, Amofah E, Florou A, Amin F, Bou-Gharios G, Jeffery R, Iredale JP, Forbes SJ. The bone marrow functionally contributes to liver fibrosis. *Gastroenterology.* 2006; 130(6):1807–1821. [PubMed: 16697743]
60. Roderfeld M, Rath T, Voswinckel R, Dierkes C, Dietrich H, Zahner D, Graf J, Roeb E. Bone Marrow Transplantation Demonstrates Medullary Origin of CD34(+) Fibrocytes and Ameliorates Hepatic Fibrosis in Abcb4(–/–) Mice. *Hepatology.* 2010; 51(1):267–276. [PubMed: 19827165]
61. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. *Annu Rev Pathol.* 2011; 6:425–456. [PubMed: 21073339]
62. Zeisberg M, Kramer K, Sindhi N, Sarkar P, Upton M, Kalluri R. De-differentiation of primary human hepatocytes depends on the composition of specialized liver basement membrane. *Mol Cell Biochem.* 2006; 283(1–2):181–189. [PubMed: 16444601]
63. George J, Chandrakasan G G. Glycoprotein metabolism in dimethylnitrosamine induced hepatic fibrosis in rats. *International Journal of Biochemistry & Cell Biology.* 1996; 28(3):353–361. [PubMed: 8920645]
64. George J, Tsutsumi M, Takase S. Expression of hyaluronic acid in Nnitrosodimethylamine induced hepatic fibrosis in rats. *International Journal of Biochemistry & Cell Biology.* 2004; 36(2):307–319. [PubMed: 14643895]
65. Nieto N, Friedman SL, Cederbaum AI. Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. *Hepatology.* 2002; 35(1):62–73. [PubMed: 11786960]
66. Muriel P. Role of free radicals in liver diseases. *Hepatol Int.* 2009; 3(4):526–536.
67. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. *Gastroenterology.* 2006; 131(3):934–945. [PubMed: 16952562]
68. De Minicis S, Bataller R, Brenner DA. NADPH oxidase in the liver: Defensive, offensive, or fibrogenic? *Gastroenterology.* 2006; 131(1):272–275. [PubMed: 16831609]
69. George J. Ascorbic acid concentrations in dimethylnitrosamine-induced hepatic fibrosis in rats. *Clin Chim Acta.* 2003; 335(1–2):39–47. [PubMed: 12927683]
70. Goto T, Mikami KI, Miura K, Ohshima S, Yoneyama K, Nakane K, Watanabe D, Otaka M, Watanabe S. Mechanical stretch induces matrix metalloproteinase 1 production in human hepatic stellate cells. *Pathophysiology.* 2004; 11(3):153–158. [PubMed: 15561512]
71. Iredale JP, Goddard S, Murphy G, Benyon RC, Arthur MJ. Tissue inhibitor of metalloproteinase-I and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes. *Clin Sci (Lond).* 1995; 89(1):75–81. [PubMed: 7671571]
72. Knittel T, Mehde M, Grundmann A, Saile B, Scharf JG, Ramadori G. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. *Histochem Cell Biol.* 2000; 113(6):443–453. [PubMed: 10933221]
73. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. *Semin Liver Dis.* 2001; 21(3):373–384. [PubMed: 11586466]
74. Iredale JP, Benyon RC, Arthur MJ, Ferris WF, Alcolado R, Winwood PJ, Clark N, Murphy G. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. *Hepatology.* 1996; 24(1):176–184. [PubMed: 8707259]
75. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, Benyon C, Iredale JP. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is



- mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. *J Biol Chem.* 2002; 277(13):11069–11076. [PubMed: 11796725]
76. Leung TM, Fung ML, Liong EC, Lau TY, Nanji AA, Tipoe GL. Role of nitric oxide in the regulation of fibrogenic factors in experimental liver fibrosis in mice. *Histol Histopathol.* 2011; 26(2):201–211. [PubMed: 21154234]
  77. Roderfeld M, Weiskirchen R, Wagner S, Berres ML, Henkel C, Grotzinger J, Gressner AM, Matern S, Roeb E. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. *FASEB J.* 2006; 20(3):444–454. [PubMed: 16507762]
  78. Cao Q, Mak KM, Ren C, Lieber CS. Leptin stimulates tissue inhibitor of metalloproteinase-1 in human hepatic stellate cells: respective roles of the JAK/STAT and JAK-mediated H<sub>2</sub>O<sub>2</sub>-dependant MAPK pathways. *J Biol Chem.* 2004; 279(6):4292–4304. [PubMed: 14625304]
  79. Yoshiji H, Kuriyama S, Fukui H. Blockade of renin-angiotensin system in antifibrotic therapy. *J Gastroenterol Hepatol.* 2007; 22 Suppl 1:S93–S95. [PubMed: 17567477]
  80. Serriere-Lanneau V, Teixeira-Clerc F, Li L, Schippers M, de Wries W, Julien B, Tran-Van-Nhieu J, Manin S, Poelstra K, Chun J, Carpentier S, Levade T, Mallat A, Lotersztajn S. The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing. *FASEB J.* 2007; 21(9):2005–2013. [PubMed: 17341687]
  81. Torok NJ. Recent advances in the pathogenesis and diagnosis of liver fibrosis. *J Gastroenterol.* 2008; 43(5):315–321. [PubMed: 18592147]
  82. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. *Ann Intern Med.* 2000; 132(7):517–524. [PubMed: 10744587]
  83. Brenner DA, Alcorn JM. Therapy for hepatic fibrosis. *Semin Liver Dis.* 1990; 10(1):75–83. [PubMed: 2186490]
  84. Takase S, Takada A, Yasuhara M, Sato H, Matsuda Y. Effects of malotilate treatment on the serum markers of hepatic fibrogenesis in liver cirrhosis. *Gastroenterol Jpn.* 1988; 23(6):639–645. [PubMed: 2851477]
  85. Fu YM, Zheng SZ, Lin JG, Ryerse J, Chen AP. Curcumin protects the rat liver from CCl<sub>4</sub>-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. *Molecular Pharmacology.* 2008; 3(2):399–409. [PubMed: 18006644]
  86. George J, Suguna L, Jayalakshmi R, Chandrakasan G. Efficacy of Silymarin and Curcumin on dimethyl nitrosamine induced liver fibrosis in rats. *Biomedicine.* 2006; 26(3–4):18–26.
  87. Kang Q, Chen A. Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells. *Br J Pharmacol.* 2009; 157(8):1354–1367. [PubMed: 19594758]
  88. Houghlum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. *Gastroenterology.* 1997; 113(4):1069–1073. [PubMed: 9322499]
  89. Aleynik SI, Lieber CS. Polyenylphosphatidylcholine corrects the alcohol-induced hepatic oxidative stress by restoring s-adenosylmethionine. *Alcohol Alcohol.* 2003; 38(3):208–212. [PubMed: 12711653]
  90. Nieto N, Cederbaum AI. S-adenosylmethionine blocks collagen I production by preventing transforming growth factor-beta induction of the COL1A2 promoter. *J Biol Chem.* 2005; 280(35):30963–30974. [PubMed: 15983038]
  91. Vercelino R, Crespo I, de Souza GF, Cuevas MJ, de Oliveira MG, Marroni NP, Gonzalez-Gallego J, Tunon MJ. S-nitroso-N-acetylcysteine attenuates liver fibrosis in cirrhotic rats. *J Mol Med.* 2010; 88(4):401–411. [PubMed: 20062961]
  92. Pinzani M, Rombouts K. Liver fibrosis: from the bench to clinical targets. *Dig Liver Dis.* 2004; 36(4):231–242. [PubMed: 15115333]
  93. Rockey DC, Chung JJ. Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. *J Invest Med.* 1994; 42(4):660–670.

94. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. *Adv Drug Deliv Rev.* 2007; 59(2–3):75–86. [PubMed: 17449137]
95. Cheng K, Yang N, Mahato RI. TGF-beta1 gene silencing for treating liver fibrosis. *Mol Pharm.* 2009; 6(3):772–779. [PubMed: 19388665]
96. Hu PF, Xie WF. Targeted RNA interference for hepatic fibrosis. *Expert Opin Biol Ther.* 2009; 9(10):1305–1312. [PubMed: 19723017]
97. Xia JR, Liu NF, Zhu NX. Specific siRNA Targeting the Receptor for Advanced Glycation End Products Inhibits Experimental Hepatic Fibrosis in Rats. *Int J Mol Sci.* 2008; 9(4):638–661. [PubMed: 19325776]
98. De Vriese AS, Tilton RG, Mortier S, Lameire NH. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. *Nephrol Dial Transplant.* 2006; 21(9):2549–2555. [PubMed: 16757496]
99. Nilsen TW. Mechanisms of microRNA-mediated gene regulation in animal cells. *Trends in Genetics.* 2007; 23(5):243–249. [PubMed: 17368621]
100. Yekta S, Tabin CJ, Bartel DP. MicroRNAs in the Hox network: an apparent link to posterior prevalence. *Nat Rev Genet.* 2008; 9(10):789–796. [PubMed: 18781158]
101. Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, Bertrand E, Filipowicz W. Inhibition of translational initiation by Let-7 MicroRNA in human cells. *Science.* 2005; 309(5740):1573–1576. [PubMed: 16081698]
102. Guo CJ, Pan Q, Cheng T, Jiang B, Chen GY, Li DG. Changes in microRNAs associated with hepatic stellate cell activation status identify signaling pathways. *FEBS J.* 2009; 276(18):5163–5176. [PubMed: 19674103]
103. Lee SO, Masyuk T, Splinter P, Banales JM, Masyuk A, Stroope A, Larusso N. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. *J Clin Invest.* 2008; 118(11):3714–3724. [PubMed: 18949056]
104. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi M, Tacke F, Trautwein C, Luedde T. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. *Hepatology.* 2011; 53(1):209–218. [PubMed: 20890893]



**Figure 1.** Key concepts involved in the activation of hepatic stellate cells and pathogenesis of hepatic fibrosis.